1. Home
  2. BMRC vs MYGN Comparison

BMRC vs MYGN Comparison

Compare BMRC & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bank of Marin Bancorp

BMRC

Bank of Marin Bancorp

N/A

Current Price

$24.67

Market Cap

438.6M

Sector

Finance

ML Signal

N/A

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

N/A

Current Price

$4.85

Market Cap

481.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BMRC
MYGN
Founded
1989
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
438.6M
481.6M
IPO Year
2007
1996

Fundamental Metrics

Financial Performance
Metric
BMRC
MYGN
Price
$24.67
$4.85
Analyst Decision
Buy
Hold
Analyst Count
4
9
Target Price
$28.00
$8.06
AVG Volume (30 Days)
87.0K
1.3M
Earning Date
04-27-2026
05-15-2026
Dividend Yield
4.08%
N/A
EPS Growth
N/A
N/A
EPS
0.24
N/A
Revenue
N/A
$771,400,000.00
Revenue This Year
$330.53
$7.19
Revenue Next Year
$6.52
$5.64
P/E Ratio
$102.54
N/A
Revenue Growth
N/A
2.33
52 Week Low
$19.14
$3.76
52 Week High
$28.48
$11.44

Technical Indicators

Market Signals
Indicator
BMRC
MYGN
Relative Strength Index (RSI) 28.75 45.66
Support Level $21.08 $4.82
Resistance Level $24.26 $5.67
Average True Range (ATR) 0.99 0.38
MACD -0.27 0.11
Stochastic Oscillator 1.15 50.00

Price Performance

Historical Comparison
BMRC
MYGN

About BMRC Bank of Marin Bancorp

Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties and others. The majority of its revenue comes from interest income.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Share on Social Networks: